Applied DNA Sciences Features Large-Scale Manufacturing Capacity for Custom DNA Sequences via Polymerase Chain Reaction (PCR) at the Molecular Med Tri-Conference 2016 in San Francisco

STONY BROOK, NY--(Marketwired - March 07, 2016) -  Applied DNA Sciences, Inc. (NASDAQ: APDN)(Twitter: @APDN), a provider of DNA-based supply chain, anti-counterfeiting and anti-theft technology, product genotyping and product authentication solutions, will be exhibiting gram-scale DNA production capability at the Molecular Med Tri-Conference from March 6^th through March 8^th. Michael Hogan, Ph.D., Vice President, Life Sciences, Applied DNA Sciences, Inc. will be presenting a luncheon lecture on Tuesday, March 8, entitled: PCR-Based DNA Manufacture at the Industrial Scale: DNA Diagnostics and Therapy in the 21st Century. He will introduce PCR-based DNA manufacture to enable the synthesis of gene-sized reagents directly from synthetic genomics, with chemical modification as needed, and with rigorous, highly simplified purification to support DNA diagnostics and therapeutics. Case studies will emphasize the substantial benefits of industrial scale PCR over cloning.

Applied DNA Sciences can assist companies that develop vaccines, diagnostics, and gene therapies, and is well-positioned as a key supplier for the research, clinical, and commercialization stages of these products.

With over 10 years of experience in the market through its acquired company, Vandalia, APDN has completed the transition of all assets and intellectual property, and has established production in the company's facilities in Stony Brook, NY. A single production unit has 1000 times the output of desktop PCR devices and requires only 10% of the lead time of plasmid-based production. PCR for large-scale production provides a high-volume, cost-effective solution for linear, double-stranded DNA from 50 to 4,500 base-pairs, Additional information can be found at http://www.adnas.com/easydna.

"We are pleased to be making our debut as Applied DNA Sciences at Tri-Con this week as we continue to expand our customer base in large-scale custom DNA production. While captive supply was a necessity for APDN in producing DNA for our traditional markets, the core competencies make us a very attractive DNA supplier to others as well," stated Dr. James Hayward, CEO and President, APDN.

About Applied DNA Sciences

We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. Our patented DNA-based solutions can be used to identify, tag, track, and trace products, to help assure authenticity, traceability and quality of products. SigNature^® DNA describes the platform ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature^® T and fiberTyping^®, targeted toward textiles and apparel, DNAnet^®, for anti-theft and loss prevention, and digitalDNA^®, providing powerful track and trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. We are also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Go to adnas.com for more information, events and to learn more about how Applied DNA Sciences makes life real and safe. Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW. 

Forward Looking Statements

The statements made by APDN in this press release may be "forward-looking" in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K filed on December 14, 2015, and our subsequent quarterly report on Form 10-Q filed on February 10, 2016 which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.